Arthur P. Bollon, Ph.D., Chariman, Founder, Chief Executive Officer 

Dr. Bollon is the Founder, Chairman, & CEO of Vitruvian BioMedical, Inc. As is an accomplished biotechnology executive, scientist and entrepreneur, he has more than 30 years of experience in biotechnology, research and development and licensing. He has directed biomedical research in academia and the biotechnology / biopharmaceutical industries and has technical expertise in Biochemistry, Microbiology and Molecular Biology – Cytokines, Taxol, Monoclonal Antibodies (MAbs), Gene Regulation and Hemoglobin. Dr. Bollon has been the Founder and CEO of four biotechnology companies where he has raised over $80 Million in financing.  Prior to VbM, Dr. Bollon was the CEO of HemoBioTech, Inc., which focused on HemoTech, a potential substitute for human red blood cells; Founder & CEO of Cytoclonal Pharmaceutics, Inc., which focused on cancer and infectious disease therapeutics and diagnostics and is now part of OPKO, Inc (NASDAQ: OPK); and Founder & CEO of Wadley Biosciences Inc./LPL, a joint venture between Wadley Cancer Center and Phillips Petroleum that focused on cancer and immune disease therapeutics and diagnostics.  He is also a co-Founder and Director of SignPath Pharma Inc. which is developing Liposome and Nano-drivatives of Curcumin for cancer therapy using technologies from MD Anderson Cancer Center, Johns Hopkins Medical Center and UNT Health Science Center. He has also successfully closed business transactions with Bristol Myers Squibb, Phillips Petroleum, Merck Sharpe & Dohme and Nuron BioTech. He has completed licensing agreements with multiple universities  including (UCLA, University of Texas at Dallas, Montana State University, University of California at San Diego, Texas Tech University, University of British Columbia and MD Anderson Cancer Center and University of Texas Southwestern Medical School).  Subsequent to his executive positions, Dr. Bollon held academic appointments at the University of Texas Southwestern Medical School as well as the University of Texas at Dallas.  He is an inventor on four patents and is the author of multiple scientific communications including Editor of “Recombinant DNA Products: Insulin, Interferon, and Growth Hormone” by CRC Press. Dr. Bollon obtained his Ph.D. with a focus on Molecular Genetics from the Waxman Institute of Microbiology at Rutgers University and was a Post-Doctoral Fellow at Yale University.

T. LaCarl Satcher, MBA, Co-Founder, Chief Financial Officer

T. LaCarl Satcher is a co-Founder of Vitruvian BioMedical, Inc. and currently serves as the Chief Financial Officer has over 30 years of experience in the capacity of businesses advisory, financial services, marketing and Management Information Services.  Mr. Satcher  oversees the financial aspects of the Company. He also assists in the due diligence structure of identifying other opportunities for acquisition and / or establishing synergies with other emerging biotechnology companies with which Vitruvian will seek to establish a relationship.  Mr. Satcher is a Managing Director of WBS Investment Partners, a firm headquarted and located in Dallas, Texas.  In this capacity for over 17 years, he has specialized in providing due diligence programs and investment banking services to structure financing (private / public) for early stage development and Mergers & Acquisitions (M&A) transactions of start-ups, emerging companies, as well as micro cap and small cap public companies.  

Rhonda R. Porterfield M.D., Co-Founder, Chief Medical Advisor 

​Dr. Porterfield is a co-Founder of Vitruvian BioMedical, Inc. and serves as the Chief Medical Advisor. As an accomplished general pathologist with special expertise in surgical pathology, she has 18 years experience as Medical Director of a hospital laboratory. After selling her Pathology practice to a medical corporation, she began contracting with biomedical companies and performs risk management and regulatory activities. Dr. Porterfield is also a writer who is expressly trained in communicating complex medical / scientific information. Her previous posts include Chief of Pathology / Medical Director of the Laboratory at Denton Community Hospital and Staff Pathologist at Dallas Pathology Associates. Before entering medical school, she was employed as a Research Technician at the University of Texas Southwestern Medical Center at Dallas, where she was involved in Cell Biology and electron microscopy. Dr. Porterfield is the author of several publications and has served on numerous hospital and pharmaceutical committees. She obtained her B.S. in Biology (Magna Cum Laude) from Texas Christian University, her M.D. from Texas Tech University Health Sciences Center School of Medicine, and completed her Pathology residency at Baylor University Medical Center, Dallas, Texas. 
WaLisa Davenport Satcher, MPA,  Executive Vice President
WaLisa Davenport Satcher serves as an Executive Vice President at Vitruvian BioMedical, Inc. where her key responsibilities include managing the Corporate Administration and Public Relations aspects of the Company.  Having extensive experience in the healthcare, biotechnology and pharmaceutical sectors, Mrs. Satcher also currently serves as a Managing Director of WBS Medical Partners, a healthcare consulting firm located in the Dallas-Fort Worth Metroplex.  Her professional career includes Corporate Executive roles within several publicly-traded biopharmaceutical companies, including, but not limited to, acting as the corporate spokesperson to the healthcare and biotech media, investors, analysts and the general public-at-large as well as being a presenter at major health care and biotechnology conferences.  Mrs. Satcher’s career span also includes overseeing the Investor Relations, Public Relations, Human Resources and Administration departments; as well as being instrumental in all of the Mergers & Acquisitions (M&A), SEC and legal activities.  Mrs. Satcher received a B.S. in Public Health Administration from Dillard University and a M.P.A. in Health Care Administration from The Graduate School at Southern University.
Bao Xi Qu, Ph.D., MD Scientific Advisor

Dr. Qu is a Co-Inventor of the Alzheimer's Disease Vaccine (US Patent No: 7,479,550 B2). Dr. Qu is also an Advisor to VITRUVIAN BioMedical, Inc. and Nuron Biotech, Inc. and is actively involved in the development of the vaccine. He is the former Assistant Professor in the Department of Neurology at the UTSWMC. Having over 25 years of experience in pharmaceutical and research science, his previous positions included being an Assistant Professor at the Center for Biomedical Invention and the Center for Molecular Cardiology at UTSWMC as well as a Research Scientist for the Division of Cell and Molecular Pathology in the Department of Pathology and the Endorphin Laboratories at the Institute of Forensic Medicine; both of the last positions held in their respective departments at the University of Zurich, Switzerland.  Dr. Qu has published several original publications and was an award recipient of the WHO scholarship at the Cancer Research Center State Hospital St. Gallen. Dr. Qu obtained his M.D. in Medicine from Jilin Medical College, his M.S. in Medicine from Tianjin Medical University and his Ph.D. in Biology and Medicine from Zurich University.

Yoh Matsumoto, M.D., Ph.D., MD Scientific Advisor

Dr. Matsumoto is a leader in the field of Alzheimer’s Disease and a pioneer in DNA Therapeutic Vaccines.  He Developed the YM7555 Therapeutic Vaccine which targets both ABeta and TAU and YM3711 which targets ABeta and for which he has obtained IND information. He has been at the Tokyo Metropolitan Institute of Medical Science and Immunotherapy Development Inc.  He will assist in the commercial development of YM7555.